Resonance Health (ASX:RHT)
ASX announcement history & article coverage
Transparent by design.
Announcments by Resonance Health (ASX:RHT) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Investor Presentation Liver Fibrosis Device & Capital Raise
Resonance Health raises $6.0 million to fund MRI growth and liver fibrosis device development
Proposed issue of securities - RHT
$6.0 Million Placement Oversubscribed
Resonance Health secures oversubscribed $6.0M placement to fund three growth programmes
Liver Fibrosis Device - EPoC Study Results
Trading Halt
Notice of Annual General Meeting/Proxy Form
Liver Fibrosis Device - Clinical Trial Results - Webinar
AGM Date & Director Nomination Closing Date
Change in Substantial Holding
Global Strategic Alliance & MSA with Image Analysis Group
Resonance Health partners with Image Analysis Group to expand global MRI clinical-trial services
Appendix 4G & Corporate Governance Statement
FY26 Full Year Results & Investor Webinar
Resonance Health reports record FY26 revenue and returns to profitability, raises FY27 guidance
FY26 Full Year Results & FY27 Guidance Investor Presentation
Resonance Health FY26 results show 42% revenue growth, return to profit, strong cashflow, and positive FY27 outlook
Appendix 4E, Full Year Statutory Accounts & Annual Report
Resonance Health reports $1.5M profit and 42% revenue growth in FY26, driven by clinical trial and imaging software expansion
FY26 Full Year Results Webinar
Resonance Health to announce FY26 results and host investor webinar on 28 August 2026
Cessation of Quarterly Reporting